Seeking Alpha

Zpini's  Instablog

Send Message
B.A. in business Management and Finances, more then 15 years of experience in private investments. In the last 2 years my focus of interest is on the Biotech sector and medical devices. My Biotech portoflio consists of compnies traded in the US and in Tel-Aviv (TASE) and some of them are dual... More
View Zpini's Instablogs on:
  • Teva Ends Its Partnership With Mediwound

    Following Teva's (NYSE:TEVA) decision to focus on certain areas of development, it announced today to Clal Biotech (Israeli traded company CBI 629014) that curing wounds is no longer a field where it wishes to participate. Hence, Teva will end it's cooperation agreement with Clal's subsidiary Mediwound.

    This comes as a big surprise to Clal Biotech investors as Mediwound has already received this September a FDA approval for its NixoBrid - a drug for treatment of level 3 burns. It is a unique gel treatment based on enzymes from pineapple cells for a rapid healing.

    Adding this to the sale of its 30% stake in Proteologics (Israeli traded company PRTL 1118116) a couple of weeks ago and the question is where does Teva heading in it's growth plans?

    Disclosure: I am long TEVA.

    Additional disclosure: I am long Clal Biotech and Proteologics

    Tags: TEVA
    Dec 11 7:38 AM | Link | Comment!
Full index of posts »
Latest Followers
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.